Cargando…
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
There are limited absolute biomarkers for determining the prognosis before first- and second-line palliative chemotherapy in unresectable pancreatic cancer (urPC) patients. To find the best prognostic inflammatory marker, we investigated relationships between overall survival (OS) and six inflammato...
Autores principales: | Shirakawa, Tsuyoshi, Makiyama, Akitaka, Shimokawa, Mototsugu, Otsuka, Taiga, Shinohara, Yudai, Koga, Futa, Ueda, Yujiro, Nakazawa, Junichi, Otsu, Satoshi, Komori, Azusa, Arima, Shiho, Fukahori, Masaru, Taguchi, Hiroki, Honda, Takuya, Shibuki, Taro, Nio, Kenta, Ide, Yasushi, Ureshino, Norio, Mizuta, Toshihiko, Mitsugi, Kenji, Akashi, Koichi, Baba, Eishi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232544/ https://www.ncbi.nlm.nih.gov/pubmed/37258608 http://dx.doi.org/10.1038/s41598-023-34962-7 |
Ejemplares similares
-
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)
por: Shibuki, Taro, et al.
Publicado: (2022) -
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
por: Fukahori, Masaru, et al.
Publicado: (2023) -
A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy
por: Kumagai, Hozumi, et al.
Publicado: (2018) -
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020) -
Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
por: Tanoue, Kenro, et al.
Publicado: (2021)